What the research found

Researchers transplanted muscle cells (myocytes) from mice into subcutaneous tissue (under the skin), where they formed functional muscle grafts. These grafts developed blood vessel networks, contracted spontaneously, and persisted in the recipients. When implanted in aged or obese mice, the grafts appeared to trigger improvements across multiple physiological systems—not just locally at the graft site, but affecting whole-body muscle function, metabolic control, and the capacity for tissue repair.

The mechanism appears to involve systemic signalling rather than direct mechanical contribution. The contracting grafts likely release factors or metabolites that circulate and influence how the body's existing tissues function, much like how endocrine organs affect distant tissues.

Why it matters for you

If translatable to humans, this hints at a fundamentally different approach to age-related decline: instead of chasing systemic hormones (testosterone, growth hormone) or signalling molecules (NAD+, metabolites), you might engineer a tissue that produces beneficial signals continuously and locally.

For MyKine users, the relevant biomarkers would shift. Rather than tracking individual peptides or hormone levels, you'd monitor downstream consequences—insulin sensitivity, VO₂ max, muscle protein synthesis, grip strength, and tissue injury recovery. The myograft would function as a long-lived "factory" improving these metrics without requiring daily dosing.

This is especially relevant if you're already using TRT or peptides: a functioning myograft might reduce the systemic load on your endocrine system or allow lower doses to achieve the same effect. It sits at the intersection of cell therapy and performance optimisation.

Caveats

• Animal model only: tested in mice; human muscle cell transplantation is not trivial and immune tolerance remains unsolved
• Mechanism unclear: the paper identifies that systemic improvements occur, but the specific circulating factors responsible are not identified
• Obesity/ageing models: unclear how results generalise to healthy, younger individuals or different metabolic states
• Early-stage technology: vascularisation, durability, and graft rejection in an immunologically intact human are unresolved
• No dose or timing data: unclear how large a graft is needed, how long benefits persist, or optimal implantation frequency